welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals Announces NEJM Publication of Landmark Phase 3 Clinical Trial for Treatment of Familial Adenomatous Polyposis
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, today announced The New England Journal of Medicine (NEJM) has published results from its landmark FAP-310 Phase 3 clinical trial of CPP-1X/sul as a pharmaco-preventive treatment for adults with familial adenomatous polyposis (FAP).
FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients. Standard of care is surgery as there are no approved drugs for FAP.
The FAP-310 Phase 3 trial compared the performance of the combination of CPP-1X (eflornithine) and sulindac (CPP-1X/sul), to each single agent alone in delaying progression to an FAP-related clinical event, such as surgery. The trial enrolled 171 patients and was conducted over many years where patients received daily treatment for 2-4 years. It was the largest prospective controlled study ever performed in FAP, and the only clinical event driven trial ever conducted.
expertly curated content related to this topic
-
Curcumin in Treating Patients With Familial Adenomatous PolyposisThis clinical trial studies curcumin in ...
-
Desmoid Clinical Trial Update & Stuff!https://www.youtube.com/watch?v=uaMKoMHE...
-
Global Quantitative Assessment of the Colorectal Polyp Burden in Familial Adenomatous Polyposis by Using a Web-based...BACKGROUND: Accurate measures of the to...
-
Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPAThis purpose of this study is to investi...
-
Combination Treatment with Curcumin and Quercetin of Adenomas in Familial Adenomatous PolyposisBACKGROUND & AIMS : Familialadenomat...
-
Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal CancersPrimary Objective: - To determine whethe...
-
Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polypos...This randomized phase II trial studies h...